Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma
Open Access
Abstract
Endometrial carcinosarcoma (ECS) represents one of the most extreme examples of tumor heterogeneity among human cancers. ECS is a clinically aggressive, high-grade, metaplastic carcinoma. At the morphological level, intratumor heterogeneity in ECS is due to an admixture of epithelial (carcinoma) and mesenchymal (sarcoma) components that can include heterologous tissues, such as skeletal muscle, cartilage, or bone. Most ECSs belong to the copy-number high serous-like molecular subtype of endometrial carcinoma, characterized by the TP53 mutation and the frequently accompanied by a large number of gene copy-number alterations, including the amplification of important oncogenes, such as CCNE1 and c-MYC. However, a proportion of cases (20%) probably represent the progression of tumors initially belonging to the copy-number low endometrioid-like molecular subtype (characterized by mutations in genes such as PTEN, PI3KCA, or ARID1A), after the acquisition of the TP53 mutations. Only a few ECS belong to the microsatellite-unstable hypermutated molecular type and the POLE-mutated, ultramutated molecular type. A common characteristic of all ECSs is the modulation of genes involved in the epithelial to mesenchymal process. Thus, the acquisition of a mesenchymal phenotype is associated with a switch from E- to N-cadherin, the up-regulation of transcriptional repressors of E-cadherin, such as Snail Family Transcriptional Repressor 1 and 2 (SNAI1 and SNAI2), Zinc Finger E-Box Binding Homeobox 1 and 2 (ZEB1 and ZEB2), and the down-regulation, among others, of members of the miR-200 family involved in the maintenance of an epithelial phenotype. Subsequent differentiation to different types of mesenchymal tissues increases tumor heterogeneity and probably modulates clinical behavior and therapy response.Keywords
Funding Information
- Instituto de Salud Carlos III (PIE15/00050, PI16/00887, CB16/12/00316, CB16/12/00231, CB16/12/00361)
- Fundación Científica Asociación Española Contra el Cáncer (AIO-aecc 2016, Grupos Coordinados Traslacionales aecc 2018)
This publication has 111 references indexed in Scilit:
- Expression profiles of carcinosarcoma of the uterine corpus—are these similar to carcinoma or sarcoma?Genes, Chromosomes and Cancer, 2011
- Micro‐RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcomaThe Journal of Pathology, 2010
- MicroRNA signatures differentiate uterine cancer tumor subtypesGynecologic Oncology, 2010
- Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteinsWorld Journal of Surgical Oncology, 2010
- The impact of multi-modal therapy on survival for uterine carcinosarcomasGynecologic Oncology, 2010
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Regulation of HIF-1α and VEGF by miR-20b Tunes Tumor Cells to Adapt to the Alteration of Oxygen ConcentrationPLOS ONE, 2009
- Molecular alterations of EGFR and PIK3CA in uterine serous carcinomaGynecologic Oncology, 2009
- Prognostic Features of Surgical Stage I Uterine CarcinosarcomaAmerican Journal of Surgical Pathology, 2007
- Uterine carcinosarcoma: Immunohistochemical studies on tissue microarrays with focus on potential therapeutic targetsGynecologic Oncology, 2007